JNJ's Rybrevant Scores FDA Approval In Lung Cancer Patients With EGFR Exon 20 Mutation

by Vandana Singh, Benzinga Editor

May 21, 2021 3:56 PM | 1 min read | Make a Comment

The FDA has approved Janssen Pharmaceutical Companies' a unit of Johnson & Johnson JNJ Rybrevant (amivantamab-vmjw) for a subset of non-small cell lung cancer (NSCLC).
The approval covers adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Researchers evaluated Rybrevant's efficacy in a study of 81 patients.
The overall response rate was 40% was reported in the treatment arm. The median duration of response was 11.1 months, with 63% of patients having a response of 6 months or more.
Price Action: JNJ shares are up 0.10% at $171.24 during the market session on the last check Friday.
Related content: Benzinga's Full FDA Calendar

Posted In: Biotech News Health Care FDA General Briefs lung cancer Non-Small Cell Lung Cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.